AR117680A1 - Núcleo susceptible de recubrimiento para una formulación de un fármaco de liberación modificada - Google Patents

Núcleo susceptible de recubrimiento para una formulación de un fármaco de liberación modificada

Info

Publication number
AR117680A1
AR117680A1 ARP190103587A ARP190103587A AR117680A1 AR 117680 A1 AR117680 A1 AR 117680A1 AR P190103587 A ARP190103587 A AR P190103587A AR P190103587 A ARP190103587 A AR P190103587A AR 117680 A1 AR117680 A1 AR 117680A1
Authority
AR
Argentina
Prior art keywords
core
modified release
release drug
weight
formulation
Prior art date
Application number
ARP190103587A
Other languages
English (en)
Inventor
Gonzlez Roberto Carlos Bravo
Yalcin Cetinkaya-Coskun
Thomas Buser
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of AR117680A1 publication Critical patent/AR117680A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Núcleo susceptible de recubrimiento para una formulación de un fármaco de liberación modificada. Un método para producir un núcleo susceptible de recubrimiento para una formulación de un fármaco de liberación modificada para administración oral. El núcleo susceptible de recubrirse tiene una elevada carga de fármaco de al menos un 70% en peso, en base al peso total del núcleo susceptible de recubrirse. El método comprende las etapas de granular una composición que comprende un fármaco y al menos un aglutinante para formar gránulos; mezclar los gránulos con un desintegrante farmacológicamente activo y opcionalmente uno o más excipientes adicionales farmacológicamente activos para formar una combinación para compresión, en la cual el desintegrante está presente en una cantidad de aproximadamente 0,5% en peso a aproximadamente 5% en peso, en base al peso total del núcleo susceptible de recubrirse; y comprimir la combinación para compresión con el uso de un método de compresión con lubricación externa para formar un núcleo susceptible de recubrirse.
ARP190103587A 2018-12-07 2019-12-09 Núcleo susceptible de recubrimiento para una formulación de un fármaco de liberación modificada AR117680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18211145.0A EP3662898A1 (en) 2018-12-07 2018-12-07 Solid composition comprising mesalazine

Publications (1)

Publication Number Publication Date
AR117680A1 true AR117680A1 (es) 2021-08-25

Family

ID=64661228

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103587A AR117680A1 (es) 2018-12-07 2019-12-09 Núcleo susceptible de recubrimiento para una formulación de un fármaco de liberación modificada

Country Status (10)

Country Link
US (1) US20220016040A1 (es)
EP (2) EP3662898A1 (es)
JP (2) JP7321267B2 (es)
KR (1) KR20210100665A (es)
CN (1) CN113226291A (es)
AR (1) AR117680A1 (es)
CA (1) CA3122031A1 (es)
MA (1) MA54375A (es)
TW (1) TWI845565B (es)
WO (1) WO2020115256A1 (es)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5614098A (en) * 1979-07-13 1981-02-10 Takeda Chem Ind Ltd Externally lubricating tablet making machine
US4539198A (en) * 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5422121A (en) 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
US5656290A (en) 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
FI20000780A (fi) 2000-04-03 2001-10-04 Novasso Oy Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
GB0203421D0 (en) 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
SI2152250T1 (sl) 2007-05-07 2020-06-30 Evonik Operations Gmbh Trdne dozirne oblike, ki vsebujejo enterično oplaščenje s pospešenim sproščanjem zdravila
KR20140011302A (ko) * 2010-10-21 2014-01-28 갈데르마 소시에떼아노님 지속-방출 정제 및 그의 제조 방법
JOP20200144A1 (ar) 2012-04-30 2017-06-16 Tillotts Pharma Ag تركيبة عقار ذو إطلاق متأخر
LT2959892T (lt) 2013-02-22 2020-12-10 Zeria Pharmaceutical Co., Ltd. Enterine danga padengta tabletė
EP2968354B1 (en) 2013-03-15 2019-11-13 Aprecia Pharmaceuticals LLC Rapidly dispersible dosage form of oxcarbazepine
EP3062776A1 (en) * 2013-10-29 2016-09-07 Tillotts Pharma AG A delayed release drug formulation

Also Published As

Publication number Publication date
TW202038914A (zh) 2020-11-01
EP3662898A1 (en) 2020-06-10
MA54375A (fr) 2022-03-16
US20220016040A1 (en) 2022-01-20
WO2020115256A1 (en) 2020-06-11
JP7321267B2 (ja) 2023-08-04
CN113226291A (zh) 2021-08-06
CA3122031A1 (en) 2020-06-11
JP2022511566A (ja) 2022-01-31
TWI845565B (zh) 2024-06-21
JP2023113832A (ja) 2023-08-16
EP3890707A1 (en) 2021-10-13
KR20210100665A (ko) 2021-08-17

Similar Documents

Publication Publication Date Title
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
BR112015018087A8 (pt) composto, composição farmacêutica e uso
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
EA201591821A1 (ru) Защищенные от несанкционированного использования фармацевтические составы
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
CL2017003209A1 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
GT201600137A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
NO20090119L (no) Sammensetning omfattende nanopartikulaert meloxicam og hydrokodon med kontrollert frigivelse
CL2011001131A1 (es) Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp)
CO6400186A2 (es) Tabletas de acetato de ulipristal
MD3310345T2 (ro) Comprimată orodispersabilă ce conține estetrol
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
BR112017010933A2 (pt) composição farmacêutica
AR095672A1 (es) Composiciones farmacéuticas que comprenden everolimus
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
BR112018072113A2 (pt) excipiente à base de proteínas para ingredientes farmacêuticos ativos
PH12014502331A1 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
ES2616017T3 (es) Composiciones que contienen sulfato de condroitina, nattocinasa y compuestos de sulfhidrilo para su uso en el tratamiento de inflamación
AR111760A1 (es) Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
PH12016501756A1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
AR117680A1 (es) Núcleo susceptible de recubrimiento para una formulación de un fármaco de liberación modificada